UP!
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q1 2023 | 2022-11-04 | 1.20 | 1.20 |
| Q4 2022 | 2022-08-11 | 1.05 | 1.05 |
| Q3 2022 | 2022-05-05 | 1.45 | 1.45 |
| Q2 2022 | 2022-02-03 | 1.27 | 1.27 |
| Q1 2022 | 2021-11-09 | 1.29 | 1.29 |
| Q4 2021 | 2021-08-05 | 0.77 | 0.77 |
| Q3 2021 | 2021-05-06 | 1.53 | 1.53 |
| Q2 2021 | 2021-02-05 | 1.74 | 1.74 |
| Q1 2021 | 2020-11-05 | 1.51 | 1.51 |
| Q4 2020 | 2020-08-06 | 1.04 | 1.04 |
| 2016-07-06 | Reiterated Rating | Goldman Sachs Group Inc. | Buy | |
| 2016-06-20 | Reiterated Rating | Leerink Swann | Outperform | $92.00 |
| 2016-06-20 | Reiterated Rating | FBR & Co. | Buy | |
| 2016-06-20 | Reiterated Rating | FBR & Co | Buy | |
| 2016-06-15 | Reiterated Rating | Morgan Stanley | Hold | |
| 2016-06-13 | Reiterated Rating | RBC Capital | Buy | |
| 2016-06-13 | Reiterated Rating | Royal Bank Of Canada | Buy | |
| 2016-06-08 | Initiated Coverage | Bank of America | Hold | |
| 2016-06-08 | Initiated Coverage | Bank of America Corp. | Hold | |
| 2016-06-07 | Reiterated Rating | Bank of America | Neutral | |
| 2016-06-01 | Downgrade | Raymond James | Outperform to Market Perform | |
| 2016-06-01 | Downgrade | Raymond James Financial Inc. | Outperform to Market Perform | |
| 2016-05-02 | Reiterated Rating | Leerink Swann | Buy | |
| 2016-04-18 | Initiated Coverage | Avondale Partners | Outperform | $111.00 |
| 2016-04-15 | Reiterated Rating | Goldman Sachs | Buy | $105.00 |
| 2016-04-15 | Reiterated Rating | Goldman Sachs Group Inc. | Buy | $105.00 |
| 2016-04-02 | Reiterated Rating | Deutsche Bank | Hold | |
| 2016-04-02 | Reiterated Rating | Deutsche Bank AG | Hold | |
| 2016-03-15 | Downgrade | Cowen and Company | Outperform to Market Perform | $99.00 to $90.00 |
| 2016-03-15 | Initiated Coverage | Credit Suisse | Outperform | $102.00 |
| 2016-03-15 | Initiated Coverage | Credit Suisse Group AG | Outperform | $102.00 |
| 2016-03-07 | Upgrade | Goldman Sachs | Buy to Conviction-Buy | |
| 2016-02-11 | Lower Price Target | RBC Capital | Outperform | $105.00 to $95.00 |
| 2016-02-02 | Reiterated Rating | FBR & Co. | Outperform | $100.00 |
| 2016-02-02 | Reiterated Rating | William Blair | Outperform | |
| 2016-02-02 | Reiterated Rating | RBC Capital | Outperform | $105.00 |
| 2016-01-12 | Reiterated Rating | Robert W. Baird | Outperform | $110.00 to $107.00 |
| 2016-01-06 | Downgrade | Raymond James | Outperform to Market Perform | |
| 2015-12-17 | Upgrade | FBR & Co. | Underperform to Market Perform | |
| 2015-12-17 | Upgrade | Goldman Sachs | Neutral to Buy | $93.00 to $100.00 |
| 2015-11-22 | Initiated Coverage | William Blair | Buy | |
| 2015-11-04 | Reiterated Rating | Leerink Swann | Buy | $100.00 to $105.00 |
| 2015-11-03 | Boost Price Target | Barclays | Overweight | $92.00 to $98.00 |
| 2015-11-03 | Boost Price Target | Deutsche Bank | Neutral to Hold | $91.00 to $100.00 |
| 2015-11-03 | Boost Price Target | RBC Capital | Outperform | $92.00 to $95.00 |
| 2015-11-03 | Lower Price Target | FBR & Co. | Outperform | $100.00 to $97.00 |
| 2015-11-03 | Boost Price Target | Barclays PLC | Overweight | $92.00 to $98.00 |
| 2015-10-21 | Boost Price Target | Cowen and Company | $100.00 to $102.00 | |
| 2015-08-26 | Reiterated Rating | William Blair | Buy | |
| 2015-07-14 | Downgrade | Evercore ISI | Buy to Hold | $91.50 |
| 2015-06-08 | Boost Price Target | Leerink Swann | Outperform | $94.00 to $100.00 |
| 2015-06-05 | Reiterated Rating | Deutsche Bank | Hold | $91.00 to $93.00 |
| 2015-03-10 | Boost Price Target | FBR & Co. | Outperform | $92.00 to $97.00 |
| 2015-03-04 | Boost Price Target | RBC Capital | Outperform | $96.00 to $107.00 |
| 2015-03-03 | Boost Price Target | Deutsche Bank | Hold | $87.00 to $91.00 |
| 2015-03-03 | Boost Price Target | Argus | Buy | $90.00 to $105.00 |
| 2015-03-02 | Reiterated Rating | Citigroup Inc. | Hold | |
| 2015-03-02 | Boost Price Target | Mizuho | Buy | $93.00 to $103.00 |
| 2015-02-02 | Downgrade | Morgan Stanley | Overweight to Equal Weight | $86.00 |
| 2015-01-30 | Boost Price Target | Barclays | Overweight | $90.00 to $92.00 |
| 2015-01-30 | Reiterated Rating | Citigroup Inc. | Hold | $89.00 to $91.00 |
| 2015-01-30 | Reiterated Rating | Deutsche Bank | Hold | $78.00 to $87.00 |
| 2015-01-30 | Boost Price Target | RBC Capital | Outperform | $90.00 to $96.00 |
| 2015-01-30 | Boost Price Target | Mizuho | Buy | $87.00 to $93.00 |
| 2015-01-29 | Boost Price Target | FBR & Co. | Outperform | $85.00 to $92.00 |
| 2015-01-28 | Downgrade | Morgan Stanley | Overweight to Equal Weight | $86.00 |
| 2015-01-08 | Boost Price Target | Barclays | Overweight | $84.00 to $90.00 |
| 2015-01-08 | Reiterated Rating | JPMorgan Chase & Co. | Hold | $75.00 to $85.00 |
| 2014-12-29 | Set Price Target | Bank of America | Buy | $86.00 to $90.00 |
| 2014-11-05 | Boost Price Target | Argus | Buy | $83.00 to $90.00 |
| 2014-10-31 | Reiterated Rating | Barclays | Overweight | $82.00 to $84.00 |
| 2014-10-31 | Reiterated Rating | FBR & Co. | Outperform | $77.00 to $85.00 |
| 2014-10-31 | Reiterated Rating | Credit Suisse | Outperform | $80.00 to $88.00 |
| 2014-10-31 | Reiterated Rating | Citigroup Inc. | Neutral | $75.00 to $83.00 |
| 2014-10-31 | Reiterated Rating | Deutsche Bank | Hold | $72.00 to $78.00 |
| 2014-10-31 | Boost Price Target | Mizuho | Buy | $77.00 to $87.00 |
| 2014-10-16 | Initiated Coverage | RBC Capital | Outperform | $90.00 |
| 2014-08-18 | Reiterated Rating | Argus | Buy | $83.00 to $71.43 |
| 2014-08-05 | Reiterated Rating | Barclays | Overweight | $77.00 to $82.00 |
| 2014-08-05 | Reiterated Rating | Credit Suisse | Outperform | $76.00 to $80.00 |
| 2014-08-05 | Boost Price Target | Leerink Swann | Outperform | $78.00 to $84.00 |
| 2014-08-04 | Reiterated | ISI Group | Buy | $77 to $78.50 |
| 2014-08-04 | Reiterated Rating | Mizuho | Buy | |
| 2014-08-04 | Boost Price Target | Evercore ISI | Buy | $77.00 to $78.50 |
| 2014-07-09 | Boost Price Target | Robert W. Baird | $80.00 to $82.00 | |
| 2014-06-02 | Reiterated Rating | Morgan Stanley | Overweight | $76.00 |
| 2014-05-21 | Reiterated Rating | Morgan Stanley | Overweight | $76.00 |
| 2014-05-05 | Lower Price Target | Credit Suisse | Outperform | $80.00 to $76.00 |
| 2014-05-02 | Reiterated Rating | Barclays | Overweight | $77.00 |
| 2014-05-02 | Lower Price Target | Mizuho | $79.00 to $77.00 | |
| 2014-05-02 | Lower Price Target | Cowen and Company | $85.00 to $82.00 | |
| 2014-05-02 | Lower Price Target | Raymond James | $77.00 to $75.00 | |
| 2014-04-03 | Reiterated Rating | Bank of America | Buy | $75.00 to $76.00 |
| 2014-03-24 | Boost Price Target | Cowen and Company | $83.00 to $85.00 | |
| 2014-03-10 | Upgrade | Ned Davis Research | Neutral to Buy | |
| 2014-03-05 | Initiated Coverage | Barclays | Overweight | $79.00 |
| 2014-03-04 | Boost Price Target | Deutsche Bank | $66.00 to $72.00 | |
| 2014-02-18 | Initiated Coverage | Citigroup Inc. | Neutral | |
| 2014-01-31 | Reiterated | FBR Capital | Outperform | $72 to $78 |
| 2014-01-31 | Boost Price Target | Sterne Agee CRT | $73.00 to $83.00 | |
| 2014-01-31 | Boost Price Target | Raymond James | $75.00 to $77.00 | |
| 2014-01-31 | Boost Price Target | FBR & Co. | Outperform | $72.00 to $78.00 |
| 2014-01-08 | Downgrade | JPMorgan Chase & Co. | Overweight to Neutral | $75.00 |
| 2013-12-11 | Reiterated | ISI Group | Buy | $65.50 to $73.50 |
| 2013-12-11 | Reiterated | FBR Capital | Outperform | $68 to $72 |
| 2013-12-11 | Boost Price Target | Evercore ISI | Buy | $65.50 to $73.50 |
| 2013-12-11 | Upgrade | Leerink Swann | Market Perform to Outperform | $60.00 to $75.00 |
| 2013-12-11 | Boost Price Target | FBR & Co. | Outperform | $68.00 to $72.00 |
| 2013-12-09 | Boost Price Target | Mizuho | Buy | $65.00 to $76.00 |
| 2013-11-20 | Initiated Coverage | Deutsche Bank | Hold | $66.00 |
| 2013-11-06 | Upgrade | Sterne Agee CRT | Neutral to Buy | $59.00 to $73.00 |
| 2013-11-05 | Boost Price Target | Argus | Buy | $65.00 to $73.00 |
| 2013-11-01 | Boost Price Target | Cowen and Company | Outperform | $60.00 to $68.00 |
| 2013-11-01 | Boost Price Target | Mizuho | Buy | $56.00 to $65.00 |
| 2013-10-29 | Initiated Coverage | FBR & Co. | Outperform | $64.00 |
| 2013-10-14 | Boost Price Target | Evercore ISI | Buy | $56.00 to $62.00 |
| 2013-10-07 | Boost Price Target | Robert W. Baird | Outperform | $60.00 to $64.00 |
| 2013-10-03 | Boost Price Target | Credit Suisse | Outperform | $58.00 to $60.00 |
| 2013-09-19 | Initiated Coverage | Sterne Agee CRT | Neutral | $48.00 |
| 2013-08-06 | ||||
| 2013-08-02 | Reiterated | ISI Group | Buy | $50 to $56 |
| 2013-07-01 | Reiterated | Mizuho | Buy | $51 to $53 |
| 2013-05-02 | Reiterated | ISI Group | Buy | $47.50 to $50 |
| 2013-03-07 | Reiterated | Mizuho | Buy | $49 to $51 |
| 2016-07-06 | Reiterated Rating | Goldman Sachs Group Inc. | Buy | |
| 2016-06-20 | Reiterated Rating | Leerink Swann | Outperform | $92.00 |
| 2016-06-20 | Reiterated Rating | FBR & Co. | Buy | |
| 2016-06-20 | Reiterated Rating | FBR & Co | Buy | |
| 2016-06-15 | Reiterated Rating | Morgan Stanley | Hold |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In CAH 556 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| Vanguard Group, Inc | 32.15M |
| BlackRock Inc. | 28.68M |
| STATE STREET CORP | 20.31M |
| BlackRock Institutional Trust Company, N.A. | 10.65M |
| PRICE T ROWE ASSOCIATES INC /MD/ | 8.20M |
| FMR LLC | 8.04M |
| GEODE CAPITAL MANAGEMENT, LLC | 5.45M |
| Invesco Ltd. | 5.16M |
| BlackRock Fund Advisors | 4.50M |
| MORGAN STANLEY | 4.43M |
| BlackRock Group LTD | 4.23M |
| NORTHERN TRUST CORP | 3.56M |
| ProShare Advisors LLC | 3.10M |
| PZENA INVESTMENT MANAGEMENT LLC | 2.73M |
| NOMURA HOLDINGS INC | 2.72M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| Barrett George S Chairman and CEO | 0.15% (518385) | CAH / ETN / |
| Kaufmann Michael C CEO, Pharmaceutical Segment | 0.06% (211849) | CAH / MSM / |
| Casey Donald M Jr. CEO, Medical Segment | 0.04% (146503) | BIOD / CAH / WSTC / XRAY / |
| Morford Craig S Chief Legal/Compliance Officer | 0.03% (109873) | CAH / RPM / |
| Henderson Jeffrey William Chief Financial Officer | 0.02% (67190) | CAH / FGEN / HALO / QCOM / |
| Giacomin Jon L CEO, Pharmaceutical Segment | 0.02% (55048) | CAH / |
| DOWNEY BRUCE | 0.01% (37985) | CAH / MNTA / |
| NOTEBAERT RICHARD C | 0.01% (35778) | AEP / AON / CAH / |
| MORRISON PATRICIA Chief Information Officer | 0.01% (34978) | CAH / SPLK / |
| Stephen Falk T EVP, Gen. Counsel & Corp. Sec. | 0.01% (32455) | CAH / |
| WATKINS CAROLE S Chief HR Officer | 0.01% (31585) | CAH / |
| DARDEN CALVIN | 0.01% (29689) | CAH / CCE / TGT / |
| KENNY GREGORY B | 0.01% (29648) | AKS / BGC / CAH / INGR / |
| Arnold Colleen F. | 0.01% (28515) | CAH / IBM / |
| COX CARRIE SMITH | 0.01% (25687) | CAH / CELG / TXN / |
| FINN JOHN F | 0.01% (21074) | CAH / GEF / |
| KING DAVID P | 0.01% (21044) | CAH / LH / |
| Blake Mark R EVP - Strategy & Corp. Dev. | 0.01% (20409) | CAH / |
| BRITT GLENN | 0.01% (18314) | CAH / TWC / XRX / |
UM